M
Marc Agronin
Researcher at University of Miami
Publications - 8
Citations - 386
Marc Agronin is an academic researcher from University of Miami. The author has contributed to research in topics: Beta (finance) & Ligand (biochemistry). The author has an hindex of 4, co-authored 8 publications receiving 297 citations.
Papers
More filters
Journal ArticleDOI
Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density
Craig Curtis,Jose Gamez,Upinder Singh,Carl H. Sadowsky,Teresa Villena,Marwan N. Sabbagh,Thomas G. Beach,Ranjan Duara,Adam S. Fleisher,Adam S. Fleisher,Kirk A. Frey,Zuzana Walker,Zuzana Walker,Arvinder Hunjan,Clive Holmes,Yavir M. Escovar,Carla X. Vera,Marc Agronin,Joel Ross,Andrea Bozoki,Mary Akinola,Jiong Shi,Rik Vandenberghe,Milos D. Ikonomovic,Paul Sherwin,Igor D. Grachev,Igor D. Grachev,G. Farrar,Adrian Smith,Christopher Buckley,Richard McLain,Stephen Salloway,Stephen Salloway +32 more
TL;DR: This study showed that flutemetamol injection labeled with radioactive fluorine 18 was safe and had high sensitivity and specificity in an end-of-life population and may increase diagnostic accuracy in cognitively impaired patients.
Journal ArticleDOI
Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
Stephen Salloway,Jose Gamez,Upinder Singh,Carl H. Sadowsky,Teresa Villena,Marwan N. Sabbagh,Thomas G. Beach,Ranjan Duara,Adam S. Fleisher,Kirk A. Frey,Zuzana Walker,Arvinder Hunjan,Yavir M. Escovar,Marc Agronin,Joel Ross,Andrea Bozoki,Mary Akinola,Jiong Shi,Rik Vandenberghe,Milos D. Ikonomovic,Paul Sherwin,Gill Farrar,Adrian Smith,Christopher Buckley,Dietmar Rudolf Thal,Michelle Zanette,Craig Curtis +26 more
TL;DR: Performance of the amyloid tracer [18F]flutemetamol was evaluated against three pathology standard of truth (SoT) measures including neuritic plaques and CERAD “ original” and “modified”.
Journal ArticleDOI
Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
David A. Wolk,Carl H. Sadowsky,Beth Safirstein,Juha O. Rinne,Juha O. Rinne,Ranjan Duara,Richard Perry,Marc Agronin,Jose Gamez,Jiong Shi,Adrian Ivanoiu,Lennart Minthon,Zuzana Walker,Steen G. Hasselbalch,Clive Holmes,Clive Holmes,Marwan N. Sabbagh,Marilyn S. Albert,Adam S. Fleisher,Paul Loughlin,Eric Triau,Kirk A. Frey,Peter Høgh,Andrea Bozoki,Roger Bullock,Eric Salmon,G. Farrar,Christopher Buckley,Michelle Zanette,Paul Sherwin,Andrea Cherubini,Fraser Inglis +31 more
TL;DR: A combination of positive results of flutemetamol F 18–labeled PET, low hippocampal volume, and cognitive status corresponded with a high probability of risk of progression from aMCI to probable AD within 36 months.
Journal ArticleDOI
Detection of Amyloid β Signature in the Lens and Its Correlation in the Brain to Aid in the Diagnosis of Alzheimer's Disease.
Charles Kerbage,Carl H. Sadowsky,Pierre N. Tariot,Marc Agronin,Gustavo Alva,F. Darell Turner,Nilan Dennis J,Anne Cameron,Gerald D. Cagle,Paul D. Hartung +9 more
TL;DR: Results of the study demonstrate the safety of the FLES system and show that amyloid brain imaging using florbetapir F18 positron emission tomography shows significant correlation with the results obtained in the eye.